Caricamento...
Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme
BACKGROUND: Imatinib, an orally administered tyrosine kinase inhibitor of PDGF receptor, c-abl and c-kit, is currently in clinical trials to assess its efficacy in malignant gliomas. Although imatinib does not readily penetrate an intact blood-brain barrier (BBB), the extent to which it distributes...
Salvato in:
| Autori principali: | , , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2009
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3927643/ https://ncbi.nlm.nih.gov/pubmed/19768386 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-009-0008-0 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|